Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Kolding Sygehus | OTHER |
| Herlev Hospital | OTHER |
| Hvidovre University Hospital | OTHER |
| Aarhus University Hospital |
Not provided
Not provided
Not provided
Not provided
Very preterm infants (<32 weeks gestation) with very low birth weight (VLBW, <1500 g) show immaturity of organs and have high nutrient requirements forgrowth and development. In the first weeks, they have difficulties tolerating enteral nutrition (EN) and are often given supplemental parenteral nutrition (PN). A fast transition to full EN is important to improve gut maturation and reduce the high risk of late-onset sepsis (LOS), related to their immature immunity in gut and blood. Conversely, too fast increase of EN predisposes to feeding intolerance and necrotizing enterocolitis (NEC). Further, human milk feeding is not sufficient to support nutrient requirements for growth of VLBW infants. Thus, it remains a difficult task to optimize EN transition, achieve adequate nutrient intake and growth, and minimize NEC and LOS in the postnatal period of VLBW infants.
Mother´s own milk (MM) is considered the best source of EN for VLBW infants and pasteurized human donor milk (DM) is the second choice, if MM is absent or not sufficient. The recommended protein intake is 4-4.5 g/kg/d for VLBW infants, when the target is a postnatal growth similar to intrauterine growth rates. This amount of protein cannot be met by feeding only MM or DM. Thus, it is common practice to enrich human milk with human milk fortifiers (HMFs, based on ingredients used in infant formulas) to increase growth, bone mineralization and neurodevelopment, starting from 7-14 d after birth and 80-160 ml/kg feeding volume per day. Bovine colostrum (BC) is the first milk from cows after parturition and is rich in protein (80-150 g/L) and bioactive components. These components may improve gut maturation, NEC protection and nutrient assimilation, even across species. Studies in preterm pigs show that feeding BC alone, or DM fortified with BC, improves growth, gut maturation and NEC resistance during the first 1-2 weeks, relative to DM, or DM fortified with conventional HMFs.On this background, we hypothesize that BC, used as a fortifier for MM or DM, can induce similar growth and better NEC and LOS resistance, than conventional fortifiers. A pilot trial is required 1) to test the feasibility and initial safety of BC as a fortifier (e.g. similar growth rates and clinical variables as conventional fortification), 2) to calculate the sample size for a later, larger RCT with NEC +LOS as the primary outcome, and 3) record paraclinical outcomes associated with type of fortifier.
The main objectives of this multicentre, non-blinded, pilot, RCT are:
Participants Parents to eligible very preterm infants admitted to the Neonatal Intensive Care Units (NICU) at Nanshan People's Hospital (NAN) and Baoan Maternal and Children's Hospital in Shenzen, China will be asked for participation.
Since this is a pilot trial, a conventional sample size calculation, using only one primary outcome, is not required. The aim is to include 200 infants (100 per group), which is expected to give sufficient strength to demonstrate effects on the chosen feasibility outcomes and secondary blood and stool variables (see protocol). Statistical analyses will be performed blindly on both intention-to-treat and per protocol basis. Continuous outcomes will be summarized as mean and standard deviation (e.g., body weight) or median and interquartile range (e.g. time to reach full enteral feeding). Binary outcomes (e.g. incidence of NEC) will be presented as counts and percentages. To test the preliminary effects of BC, clinical and para-clinical outcomes will be compared between the two groups. The estimates will be presented as relative risk and absolute risk difference, difference between means, or hazard ratio, depending on the type of outcome. The estimates will be presented with a 95% confidence interval. Further statistical analyses are described in the protocol.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Bovine Colostrum / intervention group | Experimental | Preterm infants are supplemented with bovine colostrum (BC) as a fortifier to human milk. BC is the first milk from cows after parturition and is a rich source of protein (80-150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and growth factors. The product is supplied in a sterile, powdered form and consists of unmodified, intact BC. |
|
| FM85 / control group | Active Comparator | Preterm infants are supplemented with PreNAN FM85 as fortifier to human milk. PreNAN FM85 contains partially hydrolyzed protein and maltodextrin including vitamins and minerals. The product is supplied in a powdered form. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bovine Colostrum (BC) / intervention group | Dietary Supplement | Infants randomized to the intervention group will receive a maximum of 2.8 g bovine colostrum (BC, Biofiber, Gesten, Denmark), as the HMF added to 100 ml of MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and blood urea nitrogen (BUN) levels are below 5 mmol/l. The infants starts with 1 g (0.5 g protein) BC per 100 ml human milk on the first day, increased to 2 g (1.0 g protein) on day 3, and finally 2.8 g (1.4 g protein) on day 5, if the infants only receive DM. The intervention begins if the infants meet the inclusions criteria and the intervention lasts until the infants reach post menstrual age (PMA) 34+6 weeks or are discharged home (including participating in an "early discharge program"), or are transferred to non-participating neonatal units, whichever comes first. |
| Measure | Description | Time Frame |
|---|---|---|
| Body weight | Weight gain in grams from birth to discharge from hospital. Weight at different time points will be calculated into z-scores according to a reference. Delta z-scores will be used to evaluate growth and for comparison between groups. | From start of intervention to hospital discharge, or up to 14 weeks |
| Incidence of necrotizing entercolitis (NEC) | Number of infants in each group diagnosed with necrotizing enterocolitis (NEC) defined as Bell's stage II or above (Kliegman & Walsh 1987). | From start of intervention to hospital discharge, or up to 14 weeks |
| Incidence of late-onset sepsis (LOS) | Number of infants in each group diagnosed with late-onset sepsis defined as clinical signs of infection >2 days after birth with antibiotic treatment for ≥5 days (or shorter than 5 days if the participant died) with or without one positive bacterial culture in blood or cerebral spinal fluid (CSF). | From start of intervention to hospital discharge, or up to 14 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Feeding intolerence | Proportion of days with a feeding volume less than 50% of the total planned volume per day | From start of intervention to end of study period at post menstrual age 34+6 weeks, or up to 8 weeks |
| Time to reach full enteral feeding |
| Measure | Description | Time Frame |
|---|---|---|
| Body length | Recorded as a measure of growth in cm by standardized measuring procedures | Weekly from just before to end of intervention at postmenstrual age 34+6 weeks, or up to 8 weeks |
| Head circumference |
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gitte Zachariassen, MD., PhD | Odense University Hospital | Principal Investigator |
| Per Sangild, Prof | Rigshospitalet, Denmark | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Aarhus University Hospital | Aarhus | 8200 | Denmark | |||
| Rigshospitalet (RH) |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39982063 | Derived | Yang L, Hui Y, Sangild PT, Kot WP, Aunsholt L, Zachariassen G, Jiang P-P, Nielsen DS. Gut microbiota development in very preterm infants following fortification of human milk. mSystems. 2025 Mar 18;10(3):e0091624. doi: 10.1128/msystems.00916-24. Epub 2025 Feb 21. | |
| 38587119 | Derived | Simonsen MB, Kappel SS, Aunsholt L, Moller S, Sangild PT, Zachariassen G. Mineral supplementation for very preterm infants fed fortified human milk. J Pediatr Gastroenterol Nutr. 2024 Jun;78(6):1389-1397. doi: 10.1002/jpn3.12190. Epub 2024 Apr 8. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020345 | Enterocolitis, Necrotizing |
| ID | Term |
|---|---|
| D004760 | Enterocolitis |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D035061 | Control Groups |
| ID | Term |
|---|---|
| D015340 | Epidemiologic Research Design |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D012107 | Research Design |
Not provided
Not provided
| OTHER |
| Odense University Hospital | OTHER |
| Nordsjaellands Hospital | OTHER |
A multicentre, non-blinded, pilot randomized controlled trial
Not provided
Not provided
Not provided
|
| FM85 / control group | Dietary Supplement | Infants randomized to the control group will receive a maximum of 4 g PreNAN FM85 (Nestlé, Vevey, Switzerland) as HMF, added to 100 ml MM and/or DM, when EN has reached a dose of 100-140 ml/kg/d and BUN levels are below 5 mmol/l. The infants starts with 1 g (0.35 g protein) FM85 per 100 ml human milk on the first day, which will be increased to 3 g (1.05 g protein) on day 3 and finally 4 g (1.4 g protein) on day 5, if the infants only receive DM. FM85 is the standard HMF used in all participating hospitals in Denmark. The infants will receive FM85 as the HMF as long as additional protein in the milk is needed. |
|
Number of days to full enteral feeding is reached - defined as the time when >150 ml/kg/d is reached and parenteral nutrition has been discontinued
| From birth to full enteral feeding, or up to 8 weeks |
| Days on parenteral nutrition | Number of days that the infant receives intravenous intakes of protein and/or lipid and/or glucose. | From birth to end of intervention, or up to 8 weeks |
| Length of hospital stay | Number of days in hospital, defined as days from birth until final discharge (including the days covered by an early discharge programme). | From birth until until final discharge, or up to 14 weeks |
| Blood urea nitrogen (BUN) | Blood urea nitrogen concentration is measured to evaluate the risk of excessive protein supply and immature kidney function | Weekly from just before to end of intervention at postmenstrual age 34+6 weeks, or up to 8 weeks |
| Blood minerals | Blood levels of ionized phosphate, calcium and zink are measured to evaluate the risk of inadequate or excessive dietary mineral supply | Weekly from just before to end of intervention at postmenstrual age 34+6 weeks, or up to 8 weeks |
| Blood haemoglobin | Determined to evaluate risk of anaemia and inadequate iron supply | Weekly from just before to end of intervention at postmenstrual age 34+6 weeks, or up to 8 weeks |
Recorded as a measure of head growth in cm by standardized measuring procedures
| Weekly from just before to end of intervention at postmenstrual age 34+6 weeks, or up to 8 weeks |
| Plasma amino acid levels | To determine whether individual amino acids are within their normal range. Specific attention is given to amino acids used as markers for excessive protein supply (tyrosine) and gut function (citrulline, arginine) | Prior to and after 1 and 2 weeks of intervention |
| Plasma intestinal fatty acid binding protein (i-FABP) | Determine the concentration, as a marker of gut epithelial integrity | Prior to and after 1 and 2 weeks of intervention |
| Plasma neutrophil extracellular trap (NET) components | Determine the concentration, as a marker systemic inflammation | Prior to and after 1 and 2 weeks of intervention |
| Plasma lactoferrin | Determine the concentration, as a marker systemic inflammation | Prior to and after 1 and 2 weeks of intervention |
| Plasma interleukin (IL) 8 | Determine the concentration, as a marker systemic inflammation | Prior to and after 1 and 2 weeks of intervention |
| Fecal microbiota | Determine the 16S microbiome density and diversity, as a marker for gut microbiota stability | Prior to and after 1 and 2 weeks of intervention |
| Fecal interleukin (IL) 8 | Determine concentration per g feces, as marker of gut inflammation | Prior to and after 1 and 2 weeks of intervention |
| Fecal calprotectin (S100-A8/9) | Determine concentration per g faeces, as marker of gut inflammation | Prior to and after 1 and 2 weeks of intervention |
| Fecal metabolites (short-chain fatty acids, SCFAs) | Determine concentration per g faeces, including acetate, butyrate and propionate levels, as markers of bacterial nutrient fermentation | Prior to and after 1 and 2 weeks of intervention |
| Feasibility of study design | Record parental consent rates, infant recruitment rates, proportion of incomplete datasets | From study initiation to study completion at each participating hospital, data collected from each unit by the end of the study |
| Feasibility of diet intervention | Determine by semi-quantitative questionaire evaluation, if the investigated BC product, relative to the control product, increases/decreases the work load or complications experienced by the involved clinical staff (doctors, nurses) | From study initiation to study completion at each participating hospital, data collected from each unit by the end of the study |
| Copenhagen |
| 2100 |
| Denmark |
| Herlev Hospital | Herlev | 2730 | Denmark |
| North Zealand Hospital | Hillerød | 3400 | Denmark |
| Hvidovre Hospital (HH) | Hvidovre | 2650 | Denmark |
| Kolding Hospital | Kolding | 6000 | Denmark |
| Odense University Hospital | Odense | 5000 | Denmark |
| 37565393 | Derived | Lewis AE, Kappel SS, Hussain S, Sangild PT, Zachariassen G, Aunsholt L. Trial-related blood sampling and red blood cell transfusions in preterm infants. Acta Paediatr. 2023 Dec;112(12):2486-2492. doi: 10.1111/apa.16948. Epub 2023 Aug 16. |
| 31118098 | Derived | Ahnfeldt AM, Hyldig N, Li Y, Kappel SS, Aunsholdt L, Sangild PT, Zachariassen G. FortiColos - a multicentre study using bovine colostrum as a fortifier to human milk in very preterm infants: study protocol for a randomised controlled pilot trial. Trials. 2019 May 22;20(1):279. doi: 10.1186/s13063-019-3367-7. |
| D007410 |
| Intestinal Diseases |
| D008722 | Methods |